Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme exercises option on Dyax's DX-88

GENZ exercised its option under a 1998 deal to acquire

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE